Search clinical trials for: BI 113608 PIB

Total 2218 results

Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of BI 113608 in Healthy Male Volunteers

Healthy

Germany
Boehringer Ingelheim

Completed

BI 113608 Administered as Tablets Twice Daily Over 4 Weeks in Patients With Chronic Obstructive Pulmonary Disease Associated With Chronic Bronchitis

Pulmonary Disease, Chronic Obstructive

Germany
Boehringer Ingelheim

Completed

Study to Investigate the Relative Bioavailability, Influence of Pantoprazole Coadministration and Food Effect of Different Oral Formulation of BI 113608

Healthy

Germany
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of BI 113608 in Healthy Asian and Caucasian Male Volunteers

Healthy

Korea, Republic of
Boehringer Ingelheim

Completed

First in Man Trial of BI 113608

Healthy

Germany
Boehringer Ingelheim

Completed

Bioavailability of Soft Gelatin Capsule Formulation of BI 201335 NA Compared to the Solution Formulation in Healthy Volunteers

Healthy
Boehringer Ingelheim

Completed

Relative Bioavailability of 1 mg and 10 mg BI 1356 BS as Powder in the Bottle (PIB) to 1 mg and 10 mg BI 1356 BS as Tablets as Single Oral Administration in Healthy Male Volunteers Including the Influence of Food on the Bioavailability of 10 mg BI 1356 BS

Healthy
José A. Luchsinger
National Institute on Aging (NIA); Wake Forest University

Enrolling by invitation

11C-PIB PET Study in MESA at Columbia University

Vascular Diseases | Atherosclerosis | Cognitive Impairment | Alzheimer Disease

United States
University of Southern California
National Institute on Aging (NIA); Alzheimer's Therapeutic Research Institute; Alzheimer's Clinical Trials Consortium

Recruiting

Trial-Ready Cohort-Down Syndrome (TRC-DS) (TRC-DS)

Dementia | Alzheimer Disease | Down Syndrome

United States, Spain, United Kingdom
University of Pittsburgh
Merck Sharp & Dohme LLC; RTI International; Rite Aid Corp.; Pharmacy Quality Alliance

Completed

Effect of Community Pharmacist Intervention on Adherence to Long-Term Medications (ECO-PHIL)

Medication Adherence

United States
Johns Hopkins University
National Institute on Aging (NIA)

Completed

PET Imaging Study Using [11C]PIB in Subjects With AD & Healthy Volunteers

Alzheimer's Disease

United States
Oriental Neurosurgery Evidence-Based-Study Team

Unknown

11C-PIB PET/CT in Patients With Parkinson's Disease and Parkinsonian Dementia Syndromes

Parkinson Disease

China
Washington University School of Medicine
National Institute of Neurological Disorders and Stroke (NINDS); National Institutes... and other collaborators

Recruiting

Investigations of Dementia in Parkinson Disease (PIB)

Parkinsons

United States
Avid Radiopharmaceuticals
General Electric; American College of Radiology Imaging Network

Completed

Ability Of ([18F]-AV-45) PET Scan to Distinguish Alzheimer's Disease Subjects From Cognitively Normal Individuals

Alzheimer's Disease

United States
Brigham and Women's Hospital

Unknown

Comparison of US-Guided Paravertebral and Proximal Intercostal Nerve Blocks

Pain

United States
NYU Langone Health
Icahn School of Medicine at Mount Sinai

Recruiting

The Sleep Amyloid, Slow WAve Race and Ethnicity Study (Sleep AWARE)

Alzheimer Disease

United States
University of California, San Diego

Completed

Prevention of Transmission of Hepatitis C Virus (HCV) From HCV-Viremic Organ Donor

Hepatitis C | Hepatitis C Virus Infection, Response to Therapy of

United States
University of North Carolina, Chapel Hill
Boston Children's Hospital; Medical College of Wisconsin; National Football League

Enrolling by invitation

NFL LONG Prospective Study

Concussion, Brain

United States
IRCCS San Raffaele

Completed

PET Study With 11 C-PIB to Evaluate Amyloid Protein Deposits in Mild Cognitive Disorder, Alzheimer's Disease and Early Frontotemporal Degeneration.

Alzheimer Disease
ViiV Healthcare

Completed

GSK3739937 First-Time-In-Human (FTIH) Study in Healthy Volunteers

HIV Infections

United States
University of Alabama at Birmingham

Recruiting

UAB Alzheimer's Disease Center Core Cohort - Imaging Substudy (PiB ADC)

Alzheimer Disease

United States
Mayo Clinic

Completed

Amyloid-related Imaging Abnormalities (Microbleeds) in Atypical AD

Posterior Cortical Atrophy (PCA) | Atypical Alzheimers Disease | Logopenic Variant of Primary Progressive Aphasia (LPA)

United States
Peking Union Medical College Hospital

Recruiting

[18F]Florbetazine ([18F]92) for Beta Amyloid PET Imaging in Alzheimer's Disease

Alzheimer's Disease

China
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test if Taking Different Formulations of BI 1358894 With or Without Food Influences the Amount of BI 1358894 in the Blood

Healthy

Germany
Wuhan Union Hospital, China

Recruiting

The Diagnostic Value of Hybrid PET/MR for Systemic Amyloidosis

PET/MR | Systemic Amyloidosis

China
Mayo Clinic
National Institute on Aging (NIA)

Recruiting

Molecular and Structural Imaging in Alzheimer's Disease: A Longitudinal Study

Alzheimer Disease | Alzheimer Disease, Early Onset | Amnestic Mild Cognitive Disorder | Atypical Alzheimer's Disease | Logopenic Progressive Aphasia (LPA) | Posterior Cortical Atrophy (PCA) | Amnestic Disorder | Amnestic Symptoms

United States
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 1356 BS Administered to Healthy Male Subjects

Healthy
Boehringer Ingelheim

Not yet recruiting

A Study in People With Overweight or Obesity to Test How BI 1820237, BI 456906, or a Combination of Both Affects Brain Activity

Obesity
Boehringer Ingelheim

Recruiting

A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab

Melanoma | Non-small Cell Lung Cancer (NSCLC) | Carcinoma, Squamous Cell of Head and Neck (HNSCC)

Netherlands
Boehringer Ingelheim

Completed

This Study in Healthy Men Tests How Different Doses of BI 1358894 Are Taken up in the Body and How Well They Are Tolerated. The Study Also Looks at How Food Influences the Amount of BI 1358894 in the Blood

Healthy

Germany
Boehringer Ingelheim

Completed

This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment.

Neoplasms | Carcinoma, Non-Small-Cell Lung

United States, Spain, United Kingdom, Canada, Poland
Boehringer Ingelheim

Terminated

A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread

Neoplasms | Carcinoma, Non-Small-Cell Lung | Neoplasm Metastasis

United States
Boehringer Ingelheim

Withdrawn

A Study to Test BI 754091 Alone or in Combination With BI 836880 in People Who Have Advanced Anal Cancer

Anal Canal Squamous Cell Carcinoma

Korea, Republic of
Mayo Clinic

Enrolling by invitation

Clinico-Pathologic-Genetic-Imaging Study of Neurodegenerative and Related Disorders (AND1)

Parkinson Disease | Semantic Dementia | Behavioral Variant of Frontotemporal Dementia | CBD | Apraxia of Speech | MSA - Multiple System Atrophy | FTD | PPA | PSP | PCA | LPA | Semantic Aphasia

United States
Washington University School of Medicine

Completed

Study to Evaluate Amyloid in Blood and Imaging Related to Dementia (SEABIRD)

Alzheimer Disease | Alzheimer Dementia

United States
Boehringer Ingelheim

Completed

Single Rising Dose Study With Intravenous Infusion and Subcutaneous Injection of BI 1005273 in Healthy Male Volunteers.

Healthy

Germany
Boehringer Ingelheim

Active, not recruiting

A Study in People With Advanced Cancer to Test How BI 907828 is Processed in the Body

Solid Tumors

Hungary
Boehringer Ingelheim

Terminated

A Study in Healthy Men to Find the Best Formulation of BI 894416 and to Test How This is Taken up in the Body

Healthy

United Kingdom
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics of Single Rising Oral Doses of BI 1181181 in Healthy Male Volunteers, Including Investigation of the Effect of Food on the Bioavailability of BI 1181181

Healthy

Germany
Ganesh Babulal

Recruiting

Depression and Driving (D&D)

Depression | Drive

United States
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How BI 1015550 is Taken up and Handled by the Body

Healthy

Netherlands
Boehringer Ingelheim

Completed

A Study to Find a Safe and Effective Dose of BI 1701963 Alone and in Combination With BI 3011441 in Patients With Advanced Cancer and a Certain Mutation (Kirsten Rat Sarcoma Viral Oncogene Homologue [KRAS])

Solid Tumors, KRAS Mutation

Japan
Boehringer Ingelheim

Completed

A Study to Test Different Doses of BI 765063 Alone and in Combination With BI 754091 in Japanese Patients With Different Types of Advanced Cancer (Solid Tumors)

Solid Tumors

Japan
Boehringer Ingelheim

Completed

Multiple Rising Oral Doses of BI 1060469 in Healthy Subjects and Mild Asthma Patients

Asthma

Germany
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 1021958 in Otherwise Healthy Controlled Asthmatic Subjects

Healthy | Asthma

Germany
Boehringer Ingelheim

Recruiting

A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6

Head and Neck Cancer | Colorectal Cancer | Pancreatic Cancer | Lung Cancer | Gastrointestinal Cancer | Liver Cancer

Japan
Boehringer Ingelheim

Active, not recruiting

A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours

Neoplasms | Non-squamous, Non-Small-Cell Lung Cancer

United States, Spain, Korea, Republic of, France, Hong Kong, United Kingdom, Germany, Australia, Taiwan, Poland, Russian Federation, Ukraine
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test if Different Formulations of BI 764198 With or Without Food Influence the Amount of BI 764198 in the Blood

Healthy

Belgium
Boehringer Ingelheim

Completed

A Study in Healthy Men to Measure the Amount of BI 730357 in the Blood When Taken as a Tablet

Healthy

Netherlands
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 691751 in Healthy Asian Male Volunteers

Healthy

Korea, Republic of

3

Subscribe